Patents Assigned to Schering AG
  • Patent number: 7511059
    Abstract: The invention relates to thiazolidinones of general formula (I) their production and use as inhibitors of polo-like kinases (Plk) for treating various diseases.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 31, 2009
    Assignee: Schering Ag
    Inventors: Volker Schulze, Knut Eis, Lars Wortmann, Dirk Kosemund, Olaf Prien, Gerhard Siemeister, Holger Hess-Stumpp, Uwe Eberspaecher, Damian O Arnaiz
  • Patent number: 7507725
    Abstract: The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The uptake of these compounds by and/or the binding thereof to the erythrocytes is made possible by a group of formula —SO2NR1R2, wherein R1 and R2, independently of each other, mean a hydrogen atom, an acyl group, an alkyl group, a cycloalkyl group, an aryl group, a cyano group or a hydroxy group. The inventive prodrugs enable active agents such as endogenic substances, natural substances and synthetic substances with therapeutically useful properties which have a high “first path” effect, to be administered orally effectively or significantly improve the oral activity thereof.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: March 24, 2009
    Assignee: Schering AG
    Inventors: Walter Elger, Alexander Hillisch, Annemarie Hedden, Sigfrid Schwarz, Klaus Schollkopf
  • Patent number: 7488468
    Abstract: A near infrared fluorescent contrast agent comprising a compound having three or more sulfonic acid groups in a molecule, and a method of fluorescence imaging comprising introducing the near infrared fluorescent contrast agent of the present invention into a living body, exposing the body to an excitation light, and detecting near infrared fluorescence from the contrast agent. The near infrared fluorescent contrast agent of the present invention is excited by an excitation light and emits near infrared fluorescence. This infrared fluorescence is superior in transmission through biological tissues. Thus, detection of lesions in the deep part of a living body has been made possible. In addition, the inventive contrast agent is superior in water solubility and low toxic, and therefore, it can be used safely.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: February 10, 2009
    Assignees: Schering AG, Fuji Photo Film Co., Ltd.
    Inventors: Naoto Miwa, Michihito Inagaki, Hiroaki Eguchi, Masafumi Okumura, Yoshio Inagaki, Toru Harada
  • Patent number: 7482498
    Abstract: The invention relates to a device and a process for nucleophilic fluorination of a substance, especially for synthesis of an 18F-labeled substance for examination using a positron emission tomograph. The device comprises an anion exchange device (102) for extraction of [18F]fluoride ions by means of adsorption from a target fluid, whereby the anion exchange device (102) can be charged via a supply device (101) with the target fluid; and a measurement device (104) with a measurement chamber (103) for measuring initial radioactivity of the [18F]fluoride ions, the anion exchange device (102) being arranged at least partially in the measurement chamber (103) of the measurement device (104).
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: January 27, 2009
    Assignee: Schering AG
    Inventors: Peter Maeding, Frank Fuechtner
  • Patent number: 7481993
    Abstract: The invention relates to a conjugate PT comprising (a) a peptide P and (b) a targeting moiety T; wherein the peptide P contains from 4 to 20 amino acid residues with optionally a single thiol moiety at the C- or N-terminus replacing one of these amino acid residues, and including a complexing amino acid sequence comprising (iv) a tridentate or tetradentate planar chelator containing a ligand backbone defined by a perimeter containing a single sulfur donor atom, two or three non-sulfur donor atoms, and intervening atoms between the donor atoms; and (v) a stabilizing sidechain comprising a further donor atom, the further donor atom being covalently linked to the ligand backbone of the planar chelator through two or three intervening atoms, provided that said further donor atom is neither the nitrogen nor the oxgen atom of a peptide bond and if said further donor atom is part of a heterocyclic ring, no more than one of the intervening atoms can be part of that ring; and a radioactive metal complexed to t
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: January 27, 2009
    Assignee: Schering AG
    Inventor: John E. Cyr
  • Patent number: 7468470
    Abstract: The medicinal patch for delivering a pharmaceutically effective ingredient by contact with skin has a backing layer (1), an effective-ingredient containing adherent layer (2) on the backing layer and a release layer (4) applied over the adherent layer (2). To eliminate a dirt ring deposited when the medicinal patch is finally removed from the skin, a plastic foil or film (3) is provided on an outer peripheral or edge region of the skin-contacting surface of the adherent matrix layer (2). The plastic foil or film, which does not adhere to the skin, can be made of polyester, hydrocarbon polymers or silicone polymers and preferably has a thickness of 15 to 75 ?m with a width of 1 to 3 mm. Methods of making medicinal patches of this sort are described.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: December 23, 2008
    Assignee: Schering AG
    Inventor: Stefan Bracht
  • Patent number: 7462718
    Abstract: A process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate as well as rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate at a purity of at least 98.55% is described.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: December 9, 2008
    Assignee: Schering AG
    Inventors: Hilmar Weinmann, Matthias Schneider, Michael Gottfried
  • Patent number: 7459470
    Abstract: Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: December 2, 2008
    Assignee: Schering AG
    Inventors: Alexander Ernst, Andreas Huth, Martin Krueger, Karl-Heniz Thierauch, Andreas Menrad, Martin Haberey
  • Patent number: 7456191
    Abstract: This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: November 25, 2008
    Assignee: Schering AG
    Inventors: Ulrich Luecking, Gerhard Siemeister, Rolf Jautelat
  • Patent number: 7442794
    Abstract: The invention relates to the compounds of formula I, a process for their production and their use as anti-inflammatory agents.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: October 28, 2008
    Assignee: Schering AG
    Inventors: Hartmut Rehwinkel, Stefan Baeurle, Markus Berger, Norbert Schmees, Heike Schaecke, Konrad Krolikiewicz, Anne Mengel, Duy Nguyen, Stefan Jaroch, Werner Skuballa
  • Patent number: 7435757
    Abstract: The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17?-hydroxy steroid dehydro-genase type 1.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: October 14, 2008
    Assignee: Schering AG
    Inventors: Alexander Hillisch, Olaf Peters, Christian Gege, Wilko Regenhardt, Gabriele Moeller, Dominga Deluca, Jerzy Adamski, Walter Elger, Birgitt Schneider
  • Publication number: 20080234240
    Abstract: A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.
    Type: Application
    Filed: November 20, 2004
    Publication date: September 25, 2008
    Applicant: SCHERING AG
    Inventors: Bernd Düsterberg, Jan Endrikat, Rolf Schurmann
  • Patent number: 7427390
    Abstract: This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: September 23, 2008
    Assignee: Schering AG
    Inventors: Matthias Friebe, Peter Muschick, Andreas Huth
  • Patent number: 7419972
    Abstract: The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17?-hydroxy steroid dehydrogenase type 1.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: September 2, 2008
    Assignee: Schering AG
    Inventors: Alexander Hillisch, Olaf Peters, Christian Gege, Wilko Regenhardt, Andrea Rosinus, Jerzy Adamski, Gabriele Moeller, Walter Elger, Birgitt Schneider, Ulrich Bothe
  • Patent number: 7417056
    Abstract: Compounds of general formula (IIa) or (IIb) and their use as pharmaceutical agents.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: August 26, 2008
    Assignee: Schering AG
    Inventors: Stefan Jaroch, Hartmut Rehwinkel, Heike Schaecke, Norbert Schmees, Werner Skuballa, Jan Huebner, Orlin Petrov, Matthias Schneider, Christian Dinter
  • Patent number: 7416866
    Abstract: A process for the overexpression of dehydrogenases, especially for the overexpression of ?1-dehydrogenases, in particular for the overexpression of 3-keto steroid-?1-dehydrogenases, as well as for the bacteria, plasmids and DNA sequences that can be used for the overexpression, is described.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: August 26, 2008
    Assignee: Schering AG
    Inventor: Tillmann Spelling
  • Patent number: 7417066
    Abstract: The invention relates to compounds of general Formula I, the production thereof, and the use thereof as a medicinal product.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: August 26, 2008
    Assignee: Schering AG
    Inventors: Bernd Buchmann, Martin Fritsch, Duy Nguyen, Bernd Menzenbach, Ulf Boemer
  • Patent number: 7414043
    Abstract: This invention describes the new 9?-substituted estratrienes of general formula I in which R3, R7, R7?, R13, R16 as well as R17 and R17? have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: August 19, 2008
    Assignee: Schering AG
    Inventors: Dirk Kosemund, Gerd Mueller, Alexander Hillisch, Karl-Heinrich Fritzemeier, Peter Muhn
  • Patent number: 7408060
    Abstract: This invention relates to nonsteroidal progesterone receptor modulators of general formula I, a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds. The compounds according to the invention are suitable for therapy and prophylaxis of gynecological diseases, such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea, as well as for the therapy and prophylaxis of hormone-dependent tumors and for use for female birth control as well as for hormone replacement therapy.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: August 5, 2008
    Assignee: Schering AG
    Inventors: Norbert Schmees, Ulrich Bothe, Wolfgang Schwede, Carsten Moeller, Ulrike Fuhrmann, Anja Schmidt
  • Patent number: 7385054
    Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine, and A1 and A2 have different meanings, are suitable as contrast media.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: June 10, 2008
    Assignee: Schering AG
    Inventors: Johannes Platzek, Heiko Schirmer, Hanns-Joachim Weinmann, Jose Luis Martin, Juan R. Harto